2022 saw a 25% drop in new drug approvals and a less predictable regulator.
Login or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Fresh from the biotech pipeline: fewer approvals, but biologics gain share. Nat Biotechnol 41, 174–182 (2023). https://doi.org/10.1038/s41587-022-01630-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-022-01630-6
This article is cited by
-
The devolution of biosimilars regulations
Nature Biotechnology (2025)
-
Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?
Nature Biotechnology (2025)
-
SWATH-MS insights on sodium butyrate effect on mAbs production and redox homeostasis in CHO cells
AMB Express (2024)
-
Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis
Advances in Therapy (2024)
